Health and Fitness Health and Fitness
Fri, June 17, 2011
[ 07:57 AM ] - Market Wire
GELA, de vooraanstaande samenwerkingsgroep voor l .. en, kiest Revlimid voor groot onderzoek naar foll
[ 07:45 AM ] - Market Wire
AstraZeneca Installs 7,300-Panel Solar Energy System on Wilmington Campus
[ 07:04 AM ] - Market Wire
Magellan Selects Healthyroads Coaching® to Impro .. kforce Productivity Through Enhanced EAP Services
[ 06:30 AM ] - Market Wire
Bio-Path Holdings to Present at the OneMedForum NY Conference
[ 06:00 AM ] - Market Wire
Humana Inc. to Present at the Wells Fargo Securities 2011 Healthcare Conference
[ 05:30 AM ] - Market Wire
GenMark Announces Pricing of Public Offering of Common Stock
[ 05:30 AM ] - Market Wire
Health Net Announces Appearance at Wells Fargo Conference
[ 04:43 AM ] - Market Wire
El estudio de fase II que evala los beneficios cl .. IMID® con rituximab mejorar la actividad antican
[ 04:30 AM ] - Market Wire
GELA, the Premier Cooperative Group in Adult Lymp .. REVLIMID® for Major Study in Follicular Lymphoma
[ 04:30 AM ] - Market Wire
GELA, il principale gruppo cooperativo per lo stu .. ienti adulti affetti da linfoma, ha scelto REVLIM
[ 04:30 AM ] - Market Wire
GELA, fhrende Forschungsgemeinschaft fr Lymphomer .. lt REVLIMID® fr umfangreiche Studie fr follikulr
[ 04:30 AM ] - Market Wire
REVLIMID® s©lectionn© par GELA, le principal g .. itement des patients adultes atteints de lymphome
[ 04:23 AM ] - Market Wire
Presentados los datos del estudio de fase I/II qu .. de REVLIMID® en combinacin con la quimioterapia
[ 03:32 AM ] - Market Wire
Amyris anuncia planos de expanso na sia e na rea .. laborao com a Wilmar, um dos maiores grupos globa
[ 02:16 AM ] - Market Wire
Fase-2 onderzoek evalueert klinische voordelen va .. uximab om antikankeractiviteit in mantelcellymfoo
[ 02:12 AM ] - Market Wire
Fase-1/2 gegevens ter evaluatie klinisch voordeel .. et standaard R-CHOP-chemotherapie bij patinten me
[ 01:10 AM ] - Market Wire
Cord Blood America Acquires Assets of NeoCells, an Illinois Stem Cell Storage Company
Thu, June 16, 2011
[ 11:30 PM ] - Market Wire
Data Suggests Treatment with FOLOTYN® Reverses T .. Observed in Patients with Drug-Resistant Relapse
[ 08:07 PM ] - Market Wire
Phase-I/II-Daten zur Bewertung des klinischen Nut .. tion mit R-CHOP-Standard-Chemotherapie bei Patien
[ 08:03 PM ] - Market Wire
Phase-II-Studie evaluiert klinischen Nutzen einer .. t Rituximab zur Verbesserung der Anti-Krebs-Aktiv
[ 08:02 PM ] - Market Wire
Une ©tude de phase II ©value les b©n©fices cl .. ximab pour am©liorer l'activit© anti-canc©reus
[ 05:40 PM ] - Market Wire
WellPoint Appoints Harlan Levine as Executive Vice President of Comprehensive Health Solutions
[ 05:40 PM ] - Market Wire
SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
[ 05:40 PM ] - Market Wire
FDA Grants Accelerated Approval of ISTODAX® As T .. ipheral T-Cell Lymphoma Who Have Received at Leas
[ 04:40 PM ] - Market Wire
Bioheart Set to Present at International Academy .. gress on Heart Disease, Annual Scientific Session
[ 03:00 PM ] - Market Wire
SuperGen Stockholders Approve Stock Issuance In C .. roposed Acquisition of Astex Therapeutics Limited
[ 02:18 PM ] - Market Wire
Uno studio di fase II valuta i benefici clinici d .. uximab per migliorare l'attivit anticancerogena n
[ 02:12 PM ] - Market Wire
Donn©es de phase I/II ©valuant les b©n©fices .. en association avec une chimioth©rapie standard
[ 02:11 PM ] - Market Wire
I dati di fase I/II valutano i benefici clinici d .. chemioterapia standard R-CHOP per i pazienti affe
[ 02:00 PM ] - Market Wire
MannKind to Present at the Wells Fargo Securities 2011 Healthcare Conference

MannKind to Present at the Wells Fargo Securities 2011 Healthcare Conference


Published on 2011-06-16 14:10:56 - Market Wire
  Print publication without navigation


VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Wells Fargo Securities 2011 Healthcare Conference on Thursday, June 23, 2011 at 11:15 AM (ET) at The InterContinental Hotel in Boston, Massachusetts.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at [ http://www.mannkindcorp.com ].

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at [ http://www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Contributing Sources